Mitigating the risks of post-acute sequelae of SARS-CoV-2 infection (PASC) with intranasal chlorpheniramine: perspectives from the ACCROS studies
Abstract Background The World Health Organization (WHO) declared the end of the COVID-19 (SARS-CoV-2) global public health emergency on May 5, 2023, but its long-term consequences have still been haunting the global population. Post-acute sequelae of COVID-19 (PASC) and long-term COVID-19 are seriou...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-11-01
|
| Series: | BMC Infectious Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12879-024-10211-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846148012577914880 |
|---|---|
| author | Fernando Valerio-Pascua Fernando Baires Anupamjeet Kaur Sekhon Mari L. Tesch Estela Jackeline Pineda Syed A. A. Rizvi Jarmanjeet Singh David Abraham Cortes-Bandy Amy C. Madril Jana Radwanski Anita S. Lewis Miguel Sierra-Hoffman Mark L. Stevens Franck F. Rahaghi |
| author_facet | Fernando Valerio-Pascua Fernando Baires Anupamjeet Kaur Sekhon Mari L. Tesch Estela Jackeline Pineda Syed A. A. Rizvi Jarmanjeet Singh David Abraham Cortes-Bandy Amy C. Madril Jana Radwanski Anita S. Lewis Miguel Sierra-Hoffman Mark L. Stevens Franck F. Rahaghi |
| author_sort | Fernando Valerio-Pascua |
| collection | DOAJ |
| description | Abstract Background The World Health Organization (WHO) declared the end of the COVID-19 (SARS-CoV-2) global public health emergency on May 5, 2023, but its long-term consequences have still been haunting the global population. Post-acute sequelae of COVID-19 (PASC) and long-term COVID-19 are serious concerns and present with various symptoms. Intranasal chlorpheniramine (iCPM) has been shown to decrease the viral burden of SARS-COV-2. iCPM uses decreased COVID-19 disease progression and severity in Accelerating COVID-19 Clinical Recovery in an Outpatient Setting (ACROSS)-I & III randomized control trials (RCT). Methods This prospective survey study included 259 participants in ACROSS I and III RCTs. We compared the effect of iCPM versus placebo on the reduction of PASC symptoms. A PASC questionnaire containing 17 questions regarding the most common PASC symptoms was used in this study. T-test and Pearson chi-square statistics were performed according to continuous and categorical data using STATA 17.0 Basic Edition software. Findings The iCPM cohort had a lower proportion of patients with fatigue or tiredness vs. placebo (0 Vs 17, 21, p < 0.001). iCPM cohort had a lower proportion of patients with difficulty concentrating or mental confusion (0 vs. 22, 27, p < 0.001). iCPM cohort had also a lower number of patients with difficulty in the ability to perform daily activities or work vs. placebo (1 Vs 38, 48, p < 0.001). A smaller number of patients in the iCPM cohort sought medical attention for PACS symptoms compared to placebo (0 vs. 48, 68, p < 0.001). Interpretation The use of intranasal chlorpheniramine shows promise in preventing COVID-19 progression to the often-debilitating post-COVID-19 syndrome PASC. The association between iCPM use and a lower prevalence of PASC symptoms is strong. Further studies are needed to establish the role of ICPM in preventing PASC. |
| format | Article |
| id | doaj-art-1b1738b9e2ce4af088219ed5969dcd17 |
| institution | Kabale University |
| issn | 1471-2334 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj-art-1b1738b9e2ce4af088219ed5969dcd172024-12-01T12:11:38ZengBMCBMC Infectious Diseases1471-23342024-11-012411910.1186/s12879-024-10211-8Mitigating the risks of post-acute sequelae of SARS-CoV-2 infection (PASC) with intranasal chlorpheniramine: perspectives from the ACCROS studiesFernando Valerio-Pascua0Fernando Baires1Anupamjeet Kaur Sekhon2Mari L. Tesch3Estela Jackeline Pineda4Syed A. A. Rizvi5Jarmanjeet Singh6David Abraham Cortes-Bandy7Amy C. Madril8Jana Radwanski9Anita S. Lewis10Miguel Sierra-Hoffman11Mark L. Stevens12Franck F. Rahaghi13Department of Critical Care, Hospital CEMESAUniversidad Nacional Autonoma de HondurasSleep Medicine, Kaiser PermanenteResearch and Development, Dr. Ferrer BiopharmaDepartment of Critical Care, Hospital CEMESACollege of Biomedical Sciences, Larkin UniversityDepartment of Cardiovascular Medicine, University of CaliforniaUniversidad Europea de MadridDepartment of Hospital Medicine, El Campo Memorial HospitalCitizens Medical CenterMemorial Hermann Surgical HospitalDepartment of Infectious Disease, Texas A&M Detar Family Medicine ProgramResearch Department, Texas A&M College of Medicine, Detar Family Medicine Residency ProgramDepartment of Pulmonary and Critical Care Medicine, Cleveland Clinic FloridaAbstract Background The World Health Organization (WHO) declared the end of the COVID-19 (SARS-CoV-2) global public health emergency on May 5, 2023, but its long-term consequences have still been haunting the global population. Post-acute sequelae of COVID-19 (PASC) and long-term COVID-19 are serious concerns and present with various symptoms. Intranasal chlorpheniramine (iCPM) has been shown to decrease the viral burden of SARS-COV-2. iCPM uses decreased COVID-19 disease progression and severity in Accelerating COVID-19 Clinical Recovery in an Outpatient Setting (ACROSS)-I & III randomized control trials (RCT). Methods This prospective survey study included 259 participants in ACROSS I and III RCTs. We compared the effect of iCPM versus placebo on the reduction of PASC symptoms. A PASC questionnaire containing 17 questions regarding the most common PASC symptoms was used in this study. T-test and Pearson chi-square statistics were performed according to continuous and categorical data using STATA 17.0 Basic Edition software. Findings The iCPM cohort had a lower proportion of patients with fatigue or tiredness vs. placebo (0 Vs 17, 21, p < 0.001). iCPM cohort had a lower proportion of patients with difficulty concentrating or mental confusion (0 vs. 22, 27, p < 0.001). iCPM cohort had also a lower number of patients with difficulty in the ability to perform daily activities or work vs. placebo (1 Vs 38, 48, p < 0.001). A smaller number of patients in the iCPM cohort sought medical attention for PACS symptoms compared to placebo (0 vs. 48, 68, p < 0.001). Interpretation The use of intranasal chlorpheniramine shows promise in preventing COVID-19 progression to the often-debilitating post-COVID-19 syndrome PASC. The association between iCPM use and a lower prevalence of PASC symptoms is strong. Further studies are needed to establish the role of ICPM in preventing PASC.https://doi.org/10.1186/s12879-024-10211-8COVID-19SARS-CoV-2Intranasal chlorpheniramineEfficacyRandomized clinical trialDouble-blind |
| spellingShingle | Fernando Valerio-Pascua Fernando Baires Anupamjeet Kaur Sekhon Mari L. Tesch Estela Jackeline Pineda Syed A. A. Rizvi Jarmanjeet Singh David Abraham Cortes-Bandy Amy C. Madril Jana Radwanski Anita S. Lewis Miguel Sierra-Hoffman Mark L. Stevens Franck F. Rahaghi Mitigating the risks of post-acute sequelae of SARS-CoV-2 infection (PASC) with intranasal chlorpheniramine: perspectives from the ACCROS studies BMC Infectious Diseases COVID-19 SARS-CoV-2 Intranasal chlorpheniramine Efficacy Randomized clinical trial Double-blind |
| title | Mitigating the risks of post-acute sequelae of SARS-CoV-2 infection (PASC) with intranasal chlorpheniramine: perspectives from the ACCROS studies |
| title_full | Mitigating the risks of post-acute sequelae of SARS-CoV-2 infection (PASC) with intranasal chlorpheniramine: perspectives from the ACCROS studies |
| title_fullStr | Mitigating the risks of post-acute sequelae of SARS-CoV-2 infection (PASC) with intranasal chlorpheniramine: perspectives from the ACCROS studies |
| title_full_unstemmed | Mitigating the risks of post-acute sequelae of SARS-CoV-2 infection (PASC) with intranasal chlorpheniramine: perspectives from the ACCROS studies |
| title_short | Mitigating the risks of post-acute sequelae of SARS-CoV-2 infection (PASC) with intranasal chlorpheniramine: perspectives from the ACCROS studies |
| title_sort | mitigating the risks of post acute sequelae of sars cov 2 infection pasc with intranasal chlorpheniramine perspectives from the accros studies |
| topic | COVID-19 SARS-CoV-2 Intranasal chlorpheniramine Efficacy Randomized clinical trial Double-blind |
| url | https://doi.org/10.1186/s12879-024-10211-8 |
| work_keys_str_mv | AT fernandovaleriopascua mitigatingtherisksofpostacutesequelaeofsarscov2infectionpascwithintranasalchlorpheniramineperspectivesfromtheaccrosstudies AT fernandobaires mitigatingtherisksofpostacutesequelaeofsarscov2infectionpascwithintranasalchlorpheniramineperspectivesfromtheaccrosstudies AT anupamjeetkaursekhon mitigatingtherisksofpostacutesequelaeofsarscov2infectionpascwithintranasalchlorpheniramineperspectivesfromtheaccrosstudies AT mariltesch mitigatingtherisksofpostacutesequelaeofsarscov2infectionpascwithintranasalchlorpheniramineperspectivesfromtheaccrosstudies AT estelajackelinepineda mitigatingtherisksofpostacutesequelaeofsarscov2infectionpascwithintranasalchlorpheniramineperspectivesfromtheaccrosstudies AT syedaarizvi mitigatingtherisksofpostacutesequelaeofsarscov2infectionpascwithintranasalchlorpheniramineperspectivesfromtheaccrosstudies AT jarmanjeetsingh mitigatingtherisksofpostacutesequelaeofsarscov2infectionpascwithintranasalchlorpheniramineperspectivesfromtheaccrosstudies AT davidabrahamcortesbandy mitigatingtherisksofpostacutesequelaeofsarscov2infectionpascwithintranasalchlorpheniramineperspectivesfromtheaccrosstudies AT amycmadril mitigatingtherisksofpostacutesequelaeofsarscov2infectionpascwithintranasalchlorpheniramineperspectivesfromtheaccrosstudies AT janaradwanski mitigatingtherisksofpostacutesequelaeofsarscov2infectionpascwithintranasalchlorpheniramineperspectivesfromtheaccrosstudies AT anitaslewis mitigatingtherisksofpostacutesequelaeofsarscov2infectionpascwithintranasalchlorpheniramineperspectivesfromtheaccrosstudies AT miguelsierrahoffman mitigatingtherisksofpostacutesequelaeofsarscov2infectionpascwithintranasalchlorpheniramineperspectivesfromtheaccrosstudies AT marklstevens mitigatingtherisksofpostacutesequelaeofsarscov2infectionpascwithintranasalchlorpheniramineperspectivesfromtheaccrosstudies AT franckfrahaghi mitigatingtherisksofpostacutesequelaeofsarscov2infectionpascwithintranasalchlorpheniramineperspectivesfromtheaccrosstudies |